ANIC.L

Agronomics Limited
Agronomics Limited - Solar Foods Update
3rd September 2024, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 6084C
Agronomics Limited
03 September 2024
 

3 September 2024


 Agronomics Ltd

("Agronomics" or the "Company")

Solar Foods obtains Self-Affirmed GRAS status for Solein® in the United States

Agronomics (LON:ANIC), a leading listed company in the field of cellular agriculture, is pleased to report that its portfolio company Solar Foods Oyj ("Solar Foods") has announced that it has obtained self-affirmed Generally Recognized as Safe ("GRAS") status in the US for the sale of its single-cell protein, Solein®.

Solein, produced by Solar Foods, is a novel food requiring regulatory approval in most markets before it can be sold and used in food and beverages. To achieve GRAS status, Solar Foods has conducted large-scale scientific research, and the results pertaining to food safety have been published in peer-reviewed scientific journals. Additionally, a qualified panel of experts has compiled a statement on the product's safety and intended use based on determined food categories and Solein concentrations.

Achieving GRAS status is a major step towards Solein's commercialisation and entry into the US market. This is the second approval Solar Foods has secured after the sale of food products containing Solein was approved in Singapore in September 2022.

The next step for commercialising in the US involves registering the Solar Foods production facility, Factory 01, with the US Food and Drug Administration ("FDA"), which requires a food safety plan fulfilling specific regulatory requirements. This will enable Solar Foods to start exporting products from Factory 01 in Finland to the US.

Solar Foods also aims to obtain FDA-Notified GRAS status, which entails receiving a No Questions Letter from the FDA. FDA-Notified GRAS status is likely to broaden the list of potential customers given that many will require this status to introduce foods and ingredients into product lines. Solar Foods estimates it will obtain the No Questions Letter by the end of 2026.

Chief Commercial Officer, Juan Benitez-Garcia at Solar Foods said:

"Obtaining self-affirmed GRAS status is the first step towards entering the United States. We will shortly be able to launch commercial activities in this significant new market, including marketing and sales operations, and drive our growth. So far this has been possible only in Singapore. The United States will be a significant market for us and GRAS status in the US will contribute to advancing Solein's expansion into other markets."

 Jim Mellon, Co-Founder and Executive Chair of Agronomics, said:

"We are delighted that Solar Foods has successfully achieved another significant milestone in the approval process for the commercialisation of Solein. The US regulations for food safety are both stringent and well respected globally and this approval is likely to aid the company in achieving regulatory approval in other jurisdictions. This landmark accomplishment indicates the company is on track to soon deliver products directly to customers and key retail suppliers in one of the world's largest markets.

As Agronomics' portfolio matures, we look forward to seeing other companies gain approval for their respective products in jurisdictions around the world"

For  Solar Foods' full press release please see the following link:   https://solarfoods.com/solar-foods-obtains-self-affirmed-gras-status-for-solein-in-the-united-states/

About Solein®

Solein is an all-purpose protein grown with the air we breathe: The unique bioprocess takes a single microbe, one of the billion different ones found in nature, and grows it by fermenting it using air and electricity. Solein is a nutritionally rich and versatile ingredient which can replace protein in virtually any food. Solein can also be used as a fortifier to complement the nutritional profile of various foods: it can be a source of iron, fibre and B vitamins, and it can also bring different techno-functionalities into food products. Solein is suitable for any food or product, regardless of diet. Learn more about Solein at www.solein.com.

About Solar Foods

Solar Foods produces protein using carbon dioxide and electricity. Solein production, irrespective of weather and climate conditions, liberates global protein production from the constraints of traditional agriculture. Solar Foods, founded in 2017 in Espoo, Finland by Dr Pasi Vainikka, Dr Juha-Pekka Pitkänen, Sami Holmström, Jari Tuovinen, Professor Jero Ahola, and Janne Mäkelä as a spinoff from VTT Technical Research Centre of Finland and LUT University. www.solarfoods.com.

About Agronomics

Agronomics is a leading London-listed company focussing on investment opportunities within the field of cellular agriculture. The Company has established a portfolio of over 20 companies in this rapidly advancing sector. It seeks to invest in companies owning technologies with defensible intellectual property that offer new ways of producing food and materials with a focus on products historically derived from animals. These technologies are driving a major disruption in agriculture, offering solutions to improve sustainability, as well as addressing human health, animal welfare and environmental damage. This disruption will decouple supply chains from the environment and animals and improve food security for the world's expanding population. A full list of Agronomics' portfolio companies is available at https://agronomics.im/.

For further information please contact:

Agronomics Limited

Beaumont Cornish Limited

Canaccord Genuity Limited

Cavendish Capital Markets Limited

Peterhouse Capital Limited

SEC Newgate

The Company

Nomad

Joint Broker

Joint Broker

Joint Broker

Public Relations

Jim Mellon

Denham Eke

Roland Cornish

James Biddle

Andrew Potts

Harry Pardoe

Alex Aylen (Head of Equities)

Giles Balleny

Michael Johnson

Charlie Combe

Lucy Williams

Charles Goodfellow

Bob Huxford

Anthony Hughes

+44 (0) 1624 639396

info@agronomics.im

+44 (0) 207 628 3396

+44 (0) 207 523 8000

+44 (0) 207 397 8900

+44 (0) 207 469 0936

agronomics@secnewgate.co.uk

 

Nominated Adviser

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABLGDCRUGDGSD]]>
TwitterFacebookLinkedIn